Boundless Bio stops BBI-825 trial, CMO and CBO depart; cash runway extends to 2027

Boundless Bio, Inc.

BBI-825 Phase 1/2 STARMAP trial discontinued due to lack of dose-proportional PK, increased development costs, and competitive landscape changes.
BBI-355 Phase 1/2 POTENTIATE trial on track for initial clinical data readout in H2 2025; enrollment ongoing.
Third ecDTx program targeting a kinesin for ecDNA segregation; development candidate nomination expected mid-2025, IND in H1 2026.
CMO Klaus Wagner and CBO Neil Abdollahian departing; James Freddo named Interim CMO while search for permanent CMO begins.
Cash, equivalents, and short-term investments sufficient to fund operations into 2027 through anticipated milestones.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.